TERT and neoplasm: Human telomerase (TERT) is reactivated in approximately 90% of all cancers, while in approximately 10% of tumours, telomere length is maintained, independently of TERT, by the homologous recombination‐mediated alternative lengthening of the telomere (ALT) pathway [1].